JW 0302
Alternative Names: JW-0302Latest Information Update: 31 Mar 2023
At a glance
- Originator JW Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 30 Mar 2023 Preclinical trials in Unspecified in South Korea (PO) (NCT05784155)
- 24 Mar 2023 JW Pharmaceuticals plans a phase I trial for pharmacokinetic study (In volunteers) in South Korea (PO) (NCT05784155)